Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Artivion, Inc. (NYSE: AORT), a medical device company focused on cardiac and vascular surgery and the treatment of aortic diseases. Through these filings, investors can review Artivion’s detailed financial statements, risk disclosures, material agreements and governance information.
Artivion’s periodic reports on Forms 10-K and 10-Q describe its business, which includes aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, as well as preservation services for cardiac and vascular tissues. These filings outline segment-level information, geographic reach and key risk factors associated with its aortic-focused product portfolio and international operations.
Current reports on Form 8-K document material events such as quarterly financial results, amendments to the company’s credit and guaranty agreement, real estate purchase contracts for manufacturing and office facilities, and executive leadership changes. For example, recent 8-K filings discuss an amendment that extended the maturity of term loan and revolving credit facilities and added a secured delayed draw term loan facility, as well as agreements to purchase properties supporting On-X manufacturing operations in Austin, Texas.
On Stock Titan, Artivion’s SEC filings are updated in near real time as they are posted to EDGAR. AI-powered summaries help explain complex sections of lengthy documents, such as credit agreement amendments, non-GAAP reconciliations, and detailed risk factor discussions. Investors can quickly locate annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K), and use AI-generated highlights to understand how new filings may relate to Artivion’s aortic device portfolio, clinical programs, capital structure and corporate strategy.
Filing overview: FMR LLC and Abigail P. Johnson report beneficial ownership of 2,288,030.10 shares of Artivion common stock, representing 5.4% of the class. FMR LLC discloses sole voting power of 2,285,792 shares and sole dispositive power of 2,288,030.10 shares. Abigail P. Johnson reports sole dispositive power of 2,288,030.10 shares and no voting power.
The filing certifies these shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The submission references an Exhibit 99 13d-1(k)(1) agreement and a previously incorporated power of attorney for authorized signatures.
BlackRock, Inc. has filed Amendment No. 4 to Schedule 13G revealing a 5,950,909-share position in Artivion, Inc. (AORT) as of 30 June 2025. The stake equals 13.9 % of the outstanding common stock, giving BlackRock sole voting authority over 5,884,199 shares and sole dispositive authority over all 5,950,909 shares; no shared authority is reported.
The disclosure is made pursuant to Rule 13d-1(b) with BlackRock classified as a parent holding company/control person (HC). Management certifies the shares are held in the ordinary course, without intent to influence control. The filing notes that the iShares Core S&P Small-Cap ETF, a BlackRock vehicle, independently owns more than 5 % of Artivion’s float.
A double-digit passive stake from the world’s largest asset manager enhances Artivion’s institutional ownership base and may support liquidity, but the absence of activist language suggests no immediate strategic impact.